Please login to the form below

Not currently logged in

UK launch of RebiDose for treatment of MS

Merck Serono has launched the UK's first pre-filled, single-use disposable pen for the self-administration of Rebif

Merck's division for innovative prescription pharmaceuticals, Merck Serono, has launched the UK's first pre-filled, single-use disposable pen for the self-administration of Rebif, a disease-modifying drug for the treatment of relapsing forms of multiple sclerosis (MS).

The RebiDose device is a pre-filled, pre-loaded, single-use disposable pen and is the first and only injection delivery device that needs no assembly or priming by the patient.

According to MS nurse specialist at Herefordshire PCT, Del Thomas: "The simplicity of the RebiDose pen may be ideal for those patients with MS who have significant cognitive, visual or dexterity impairment. The needle is hidden and the rubber grips can maximise control by the patient throughout the entire injection process."

RebiDose pens are available in strengths of 22mcg and 44mcg as well as the titration pack for initiation of treatment. Each pen can be stored in the fridge for up to 18 months, and at room temperature of up to 25 degrees for a single period of 14 days, giving patients flexibility with storage conditions when travelling. 

RebiDose has been approved in the EU. While the UK was the first to launch RebiDose, other European countries are expected to follow shortly.

3rd November 2010


Featured jobs

Subscribe to our email news alerts


Add my company
Bedrock Healthcare Communications

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

Waking the sleeping giant
The lights are coming on for healthcare delivery in Africa...
How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...